Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
Data from INSERM advance knowledge in immunization
April 29th, 2009
"In a recent vaccination trial assessing the immuno-genecity of an NY-ESO-1 (ESO) recombinant protein administered with Montanide and CpG, we have obtained evidence that this vaccine induces specific cytolytic T lymphocytes (CTL) in half of the patients. Most vaccine-induced CTLs were directed against epitopes located in the central part of the protein, between amino acids 81 and 110," researchers in France report. "This immunodominant region, however, is distinct from another ESO CTL region, 157-165, that is a frequent target Of Spontaneous CTL responses in A2(+) patients bearing ESO+ tumors. In this study, we have investigated the CTL responses to ESO 157-165 in A2(+)...
Source: Vaccine Weekly (2009-04-29)
|
